Lantern Pharma to Present Preclinical Data On The Efficacy Of LP-284 For Mantle Cell Lymphoma At The Society Of Hematologic Oncology Annual Meeting September 28

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin’s lymphomas at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, Sept. 28 – Oct. 1, 2022, in Houston, TX.

LP-284 is a next generation acylfulvene that has a synthetically lethal mechanism of action in cancers with impaired DNA damage repair (DDR) pathway genes. In Lantern’s preclinical testing, LP-284 has shown in vitro and in vivo anti-tumor potency across a range of non-Hodgkin’s B-cell lymphomas. Of the lymphomas tested to date, LP-284 had the greatest potency against numerous MCL cell lines, including those that are resistant to the standard-of-care (SOC) agents Ibrutinib and Bortezomib. In the US, MCL is estimated to be diagnosed in around 4,500 patients each year and represents an approximate $200 million in annual therapy sales.

Lantern’s LP-284 program has been accelerated and de-risked using A.I. insights and biological modeling powered by RADR®. Lantern has been able to advance LP-284 from initial RADR® insights regarding anti-cancer activity and potential mechanisms of action in hematological cancers, to selection of specific subtypes of lymphomas with superior response, to late stage IND enabling studies and initial design of first in human clinical trials in less than 2 years. Lantern is planning on an IND submission for LP-284 in Q1 2023 and anticipates launching a Phase 1 clinical trial in Q2 2023.

Details of the poster presentation are listed below and can be found on the SOHO website. A full version of the poster will be available on Lantern’s website on October 3, 2022.

Title: LP-284 – A Highly Potent Small Molecule Targeting Mantle Cell Lymphoma

Date and Time: September 28, 2022, 5:05pm CT

Poster Number: MCL-319

Presenter: Jianli Zhou, Lantern Pharma

Total
0
Shares
Related Posts